Stockreport

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]

Spyre Therapeutics, Inc.  (SYRE) 
PDF SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now ex [Read more]